Drug
Ascrinvacumab clinical trials
Also written PF-03446962.
- studies test it
- 9
- open now
- 1
- in phase 3
- 0
- first study started
- 2007
Keep track of what changes. Save the ascrinvacumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 3
Suzhou Kintor Pharmaceutical Inc, (3) · Pfizer (3) · NCIC Clinical Trials Group (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Duke University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ascrinvacumab is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Phase Ib/II Study of GT90001 Combined With KN046 in Solid TumorsRecruitingPhase 1/2Suzhou Kintor Pharmaceutical Inc,NCT04984668Written as GT90001+KN046
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingPhase 2Suzhou Kintor Pharmaceutical Inc,NCT05178043Written as GT90001
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedPhase 1/2Suzhou Kintor Pharmaceutical Inc,NCT03893695Written as GT90001 and Nivolumab
- A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural MesotheliomaCompletedPhase 2NCIC Clinical Trials GroupNCT01486368Written as PF-03446962
- PF-03446962 in Relapsed or Refractory Urothelial CancerCompletedPhase 2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT01620970Written as PF03446962
- Safety Study of Regorafenib With PF-03446962 to Treat Colorectal CancerCompletedPhase 1Duke UniversityNCT02116894Written as PF-03446962
- Asian Phase I Study Of PF-03446962CompletedPhase 1PfizerNCT01337050Written as PF-03446962
- A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver CancerTerminatedPhase 2PfizerNCT01911273Written as PF-03446962
- A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid TumorsCompletedPhase 1PfizerNCT00557856Written as PF-03446962
Codes
What other systems call ascrinvacumab · ClinicalTrials.gg INT006145
- MeSH (NLM) C575087ascrinvacumabOne source NLM
- UNII (FDA) 716FQ5REVOASCRINVACUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q19903360AscrinvacumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91073AscrinvacumabOne source FDA
- DrugBank DB12261One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575087 | ascrinvacumab | One source NLM |
| UNII (FDA) | 716FQ5REVO | ASCRINVACUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19903360 | Ascrinvacumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91073 | Ascrinvacumab | One source FDA |
| DrugBank | DB12261 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.